Opus Genetics, Inc.·4

Mar 18, 4:11 PM ET

Zaremba Rabourn Amy 4

Research Summary

AI-generated summary

Updated

Opus Genetics (IRD) Amy Zaremba, Head of FinQA, Sells Shares

What Happened
Amy Zaremba, Head of Financial Quality Assurance at Opus Genetics (IRD), disposed of 2,816 shares on March 16, 2026 at $5.25 per share, for gross proceeds of $14,770. The Form 4 was filed March 18, 2026. This was a sale (not a purchase) and therefore is typically interpreted as a routine disposition rather than a bullish insider purchase.

Key Details

  • Transaction date: 2026-03-16; filing date: 2026-03-18.
  • Transaction: Sale of 2,816 shares at $5.25 per share; total proceeds $14,770.
  • Method: Reported as open market or private sale (S).
  • Footnote: The sale was automatic to satisfy tax withholding obligations arising from a vesting and settlement of restricted stock units (RSUs); it was not a discretionary trade by the reporting person (Footnote F1).
  • Shares owned after transaction: Not specified in the provided filing summary.
  • Timeliness: Filed two days after the transaction (within the typical Form 4 reporting window).

Context
Tax-withholding sales tied to RSU vesting are common and usually administrative (they do not necessarily reflect the insider’s market view). The dollar amount here ($14.8k) is relatively small compared with many executive trades and was executed to meet withholding requirements rather than as an investment decision.